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1. Introduction 
Despite the number of rapid reviews published within Health Technology Assessments (HTA) over 
recent years, there is no agreed and tested methodology and it is unclear how rapid reviews differ 
from systematic reviews (Harker and Kleijnen 2012).  The use of “rapid reviews” is increasing, driven 
primarily by this need to engage with policy makers, healthcare professionals, and consumers in a 
timely manner to provide evidence-based recommendations pertaining to healthcare activities and 
decisions.  However, while this concept of rapid review has been prominent in the discourse 
surrounding HTA for some time, the HTA community is yet to reach a consensus regarding their 
validity and the most appropriate methodology to use in their preparation (Watt et al. 2008).   
Methods that limit searching by dates, databases, language and sources beyond electronic, and 
limiting study selection, data extraction and quality assessment to single-individual, accelerate the 
process, but may lead to relevant information being missed and biases being introduced (Ganann et al 
2010).  Restricting the scope for study inclusion, e.g., only recent studies or on studies conducted at 
the national level, and restricting depth of the analysis (e.g., reporting only overall findings), might 
also be considered to reduce steps in the review process (Abrami et al 2010).  However, bias may be 
introduced including selection bias and publication bias.  Studies might be missed by limiting the 
number of databases searched and reviewers involved in study selection.  Additionally, rapid data 
extraction may miss some important information.  One other approach is through a summary of 
existing review evidence (Chambers and Wilson 2012;Khangura et al. 2012).  However, this method 
also relies on the quality and inclusivity of review methodology of existing reviews.  Indeed, further 
research on this topic has been recommended in order to enhance understanding of rapid review 
limitations (Ganann et al 2010;National Collaborating Centre for Methods and Tools 2010). 
Here we report a de novo method for rapid review, using a combination of randomised controlled trial 
(RCT) data extracted from existing reviews (without obtaining the original RCT publications), 
combined with a fully comprehensive systematic search to identify both RCTs potentially missed by 
previous reviews and RCT evidence published subsequent to existing reviews.  The method was used 
as part of a Health Technology Assessment (HTA) short report of treatments for premature 
ejaculation (PE) (Cooper et al. 2015).  Here we also present a case study comparing the rapid review 
results for one of the treatments of interest - selective serotonin reuptake inhibitors (SSRIs) - with 
results had a full systematic review been undertaken.  This was done by obtaining the original RCT 
articles reported in reviews to assess the accuracy and completeness of review reporting.   
In this paper we address the following research question:  
How does the validity of a rapid review method in which a systematic search is run but data from 
RCTs identified by the search that are already reported in existing reviews are extracted from those 
reviews (rather than obtain each RCT publication), and data from RCTs not reported in any existing 
review are extracted directly from the RCT publication, compare with full systematic review methods 
in which all RCTs identified by the search are obtained in full and data extracted? 
1.1. Aims 
The aims of this study were: 
1. to evaluate a rapid review method in which RCT data were extracted from existing 
reviews and additional RCTs not already captured by any review,  
2. to assess whether this was a reliable method in terms of study identification, data 
completeness, data accuracy, and information on study quality and 
3. to assess whether the conclusions of our rapid review would have been any different if 
undertaken using a traditional full systematic review data extraction method. 
2. Rapid review methods 
As a case study we used a rapid systematic review undertaken as part of a HTA short report (Cooper 
et al in 2015).  The aim of the HTA short report was to systematically review the evidence base for 
all behavioural and pharmacological interventions in the management of PE.  The review of the 
evidence was undertaken in accordance with the general principles recommended in the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 
(http://www.prisma-statement.org/). 
We initially ran full systematic review searches for the HTA short report that identified 102 RCTs 
across several interventions (behavioural, topical and systemic treatments.  In addition to a narrative 
synthesis, we also wanted to update the evidence base by pooling data across all existing RCTs in a 
meta-analysis to produce contemporary effect estimates of treatment effectiveness where possible 
within the timescale (12 weeks).  Therefore, we developed a method which involved synthesising 
evidence from RCTs extracted directly from existing systematic reviews, together with evidence 
extracted from further published RCTs.  Single-arm randomised crossover design studies (participants 
randomised to different intervention periods) were excluded in the meta-analysis.  Pooling data from 
participants randomised to different intervention periods as if the trial were a parallel group trial 
results in double-counting of participants in the analysis which constitutes a unit of analysis error 
(Higgins et al. 2011b).  Theses and dissertations were not included.  Non-English publications were 
included where sufficient data could be extracted from an English-language abstract or tables.  For 
this case study we considered evidence from one treatment option in the HTA short report – SSRIs.   
2.1. Searches 
Comprehensive, full systematic review searching was undertaken for the HTA short report.  The 
following electronic databases were searched from inception to 6 August 2013 for published and 
unpublished research evidence: MEDLINE; Embase; Cumulative Index to Nursing and Allied Health 
Literature (CINAHL); The Cochrane Library including the Cochrane Systematic Reviews Database 
(CDSR), Cochrane Controlled Trials Register (CCRT), Database of Abstracts of Reviews of Effects 
(DARE) and the Health Technology Assessment (HTA) database; ISI Web of Science (WoS), 
including Science Citation Index, and the Conference Proceedings Citation Index-Science.  Full 
search terms are reported elsewhere (Cooper et al 2013).  The U.S. Food and Drug Administration 
(FDA) website and the European Medicines Agency (EMA) website were also searched.  All citations 
were imported into Reference Manager Software and any duplicates deleted.  Search filters were 
applied for RCTs, systematic reviews, and general reviews and guidelines. 
2.2. Methodological quality assessment of existing reviews and RCTs 
As part of the rapid review for the HTA short report, the methodological quality of existing systematic 
reviews was assessed using the AMSTAR checklist (Shea et al. 2007).  The tool consists of 11 items 
assessing: a priori design; duplicate study selection and data extraction; comprehensive literature 
searching; the use of publication type as an inclusion criteria; reporting of included/excluded studies; 
reporting of characteristics of included studies; quality assessment of included studies; use of study 
quality in forming conclusions; methods used to combine findings of studies; assessment of 
publication bias; and reporting of conflict of interest (Shea et al. 2007).  A quality assessment of 
RCTs already included in reviews was not undertaken.  Methodological quality of RCTs not already 
captured by reviews was assessed using the Cochrane Collaboration risk of bias assessment criteria 
(Higgins et al. 2011a).  This tool addresses specific domains, namely: sequence generation, allocation 
concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data and selective outcome reporting.   
2.3. Data extraction for rapid review 
Within the rapid review for the HTA short report, outcome data from RCTs reported in reviews were 
extracted directly from existing reviews.  For SSRIs, eleven existing reviews were identified and it 
was possible to check the data across these reviews for concordance (Cong et al. 2012;Huang et al. 
2009;Luo et al. 2012;McCarty and Dinsmore 2012;McMahon 2012;McMahon and Porst 
2011;Moreland and Makela 2005;Richardson et al. 2005;Waldinger et al. 2004a;Wang et al. 
2007;Wang et al. 2010).  Outcome data from RCTs not reported in reviews was extracted from the 
RCT publication.  One reviewer performed data extraction of each included study.  All numerical data 
were then checked against the original article by a second reviewer.   
2.4. Evaluating accuracy and completeness of rapid review method 
Following completion of the rapid review for the HTA short report, a full systematic review was 
undertaken for one intervention (SSRIs) for this case study.  All potentially relevant RCTs relating to 
SSRIs for PE, as identified by the HTA short report searches, were obtained in full.  In order to 
evaluate the accuracy and completeness of the rapid review method, the original publications for all 
RCTs reported in existing reviews were checked against the data reported within reviews.  
Methodological quality of all RCTs was assessed using the Cochrane Collaboration risk of bias 
assessment criteria (Higgins et al 2011a).  Any other quality assessment information for RCTs 
reported in existing reviews was extracted for comparative purposes.  Relevant RCTs identified by the 
searches were also checked against the reviews to identify any RCTs that would have been missed 
had existing reviews been used as the only source of identifying RCTs up to the review’s reported 
search date.  
A summary of the comparison between the de novo rapid review method reported here and the full 
systematic review method is presented in Table 1. 
Table 1: Comparison of de novo rapid review method with full systematic review method 
Review elements Rapid review method used here Full systematic review method 
Literature searching Full literature search of MEDLINE 
and other key databases 
supplemented with searching of 
reference lists of systematic 
reviews and included RCTs 
Full literature search of MEDLINE 
and other key databases 
supplemented with searching of 
reference lists of systematic 
reviews and included RCTs 
Study selection Two reviewers sifted searches for 
all relevant RCTs, identifying those 
already included in existing 
reviews 
Two reviewers sifted searches for 
all relevant RCTs 
Data extraction Data extracted by one reviewer and 
numerical data checked by second 
reviewer of RCT data reported in 
existing reviews and data directly 
from RCT publications not in 
existing reviews 
Data extracted by one reviewer and 
numerical data checked by second 
reviewer of all RCTs directly from 
original RCT publication 
Review elements Rapid review method used here Full systematic review method 
Quality assessment Quality of existing reviews of RCT 
data assessed using AMSTAR 
Quality of RCTs within existing 
reviews not assessed (RCT 
publications reported in existing 
reviews were not initially obtained 
as beyond the scope of the HTA 
short report) 
Quality of RCTs not captured by 
existing reviews assessed using 
Cochrane risk of bias criteria 
Quality of all RCTs assessed using 
Cochrane risk of bias criteria 
 
 
3. Results 
3.1. Search results 
The searches for all treatments for PE for the HTA short report identified 2,283 citations.  Of these, 
2,181 citations were excluded, 2,174 from title and/or abstract information and seven that we were 
unable to obtain.  A total of 41 RCTs that evaluated an SSRI against a comparator (placebo, no 
therapy, another SSRI, or another agent) were identified and were included in both the rapid review 
for the HTA short report and the full systematic review.  Twenty-five of these RCTs (Atmaca et al. 
2002;Atmaca et al. 2003;Biri et al. 1998;Buvat et al. 2009;Kara et al. 1996;Kaufman et al. 
2009;Manasia et al. 2003;Mattos et al. 2008;McMahon 1998;McMahon et al. 2010;Mendels et al. 
1995;Murat Basar et al. 1999;Panshou and Xie 2004;Pryor et al. 2006;Safarinejad and Hosseini 
2006;Safarinejad 2008;Safarinejad 2006;Waldinger et al. 1994;Waldinger et al. 1997;Waldinger et al. 
1998;Waldinger et al. 2001a;Waldinger et al. 2001b;Waldinger et al. 2003;Yilmaz et al. 1999;Zhou 
2007) had been previously included by eleven systematic reviews (Cong et al 2012;Huang et al 
2009;Luo et al 2012;McCarty & Dinsmore 2012;McMahon 2012;McMahon & Porst 2011;Moreland 
& Makela 2005;Richardson et al 2005;Waldinger et al 2004a;Wang et al 2007;Wang et al 2010).  
Data from these 25 RCTs were extracted from the systematic reviews they were reported in for the 
rapid review, and directly from the RCT publication obtained in full for the full systematic review.   
3.2. Methodological quality of existing reviews 
The search methodology and inclusion criteria for studies were varied across existing systematic 
reviews.  The overall AMSTAR (Shea et al 2007) quality score was 1 out of 11 in four reviews 
(Huang et al 2009;Luo et al 2012;Richardson et al 2005;Waldinger et al 2004a), 2 out of 11 in three 
(McCarty & Dinsmore 2012;McMahon & Porst 2011;Wang et al 2007), 3 out of 11 in one review 
(Cong et al 2012), and 5 out of 11 in one (McMahon 2012).  Two reviews scored 0 out of 11 
(Moreland & Makela 2005;Wang et al 2007).  The search methodology and inclusion criteria for 
studies varied across these reviews, as did the included RCTs.  None of the reviews reported 
independent double data extraction and only four reported an assessment of study quality (Cong et al 
2012;Huang et al 2009;Luo et al 2012;Wang et al 2010).  The body text of three of the reviews was in 
Chinese language which limited full AMSTAR assessment (assessed from English language abstract 
and any other English language text) (Huang et al 2009;Luo et al 2012;Wang et al 2010).  Overall, the 
methodological quality of existing reviews was considered as being low.  A summary of the reviews 
including the number of RCTs included and the AMSTAR quality assessment is presented in (Table 
2).  
 Table 2. Summary of methodological quality (AMSTAR) of existing systematic reviews 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
Cong 2012(Cong 
et al 2012) 
(China) 
 
Systematic review 
and meta-analysis 
Fluoxetine 
(SSRI) vs. 
placebo 
MEDLINE, 
EMBASE, 
PubMed, Ovid, 
CENTRAL, 
CBM and CNKI 
database July 
1996 to May 
2012 
Google Scholar, 
Medical Matrix 
and other search 
engines on the 
Internet. Hand 
searching 
references lists (not 
specified which). 
Contact with 
experts in the field 
and corresponding 
authors (assume of 
included trials). 
Five(Kara et al 1996;Mattos et 
al 2008;Panshou & Xie 
2004;Waldinger et al 
1998;Yilmaz et al 1999) 
AMSTAR score, 3/11: 
 - comprehensive literature 
search 
 - study quality assessed* 
 - publication bias assessed 
Potentially missed: two 
(Ahn et al 1996;Culba et al 
2008) 
Huang 
2009(Huang et 
al 2009) 
(China) 
 
Systematic review 
and meta-analysis 
Any SSRI MEDLINE, Jan 
1950 to Mar 
2008; EMBASE, 
Jan 1950 to Mar 
2008; The 
Cochrane 
Library, Issue I 
2008; and China 
National 
Knowledge 
Infrastructure 
(CNKI), Jan 
1979 to Mar 
2008 
None reported Thirteen(Atmaca et al 
2002;Atmaca et al 2003;Biri et 
al 1998;Kara et al 1996;Mattos 
et al 2008;McMahon and Touma 
1999;Mendels et al 
1995;Panshou & Xie 
2004;Safarinejad & Hosseini 
2006;Safarinejad 
2006;Waldinger et al 
1998;Yilmaz et al 1999;Zhou 
2007) 
AMSTAR score, 1/11: 
 - study quality assessed† 
Potentially missed: four 
(Ahn et al 1996;Arafa & 
Shamloul 
2006;Giammusso et al 
1997;Safarinejad 2007)  
 
Published subsequent to 
reported search date: nine 
(Farnia et al 2009;Khelaia 
et al 2012;Lee et al 
2012;Nada et al 2009;Nada 
et al 2012;Rezakhaniha & 
Sirosbakht 2010;Shang et 
al 2012;Tuncel et al 
2008;Weixing et al 2012) 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
Luo 2012(Luo et 
al 2012) 
(China) 
 
Systematic and 
meta-analysis 
Dapoxetine 
(SSRI) 
PubMed, 
BIOSIS 
Previews, The 
Cochrane 
Library, China 
National 
Knowledge 
Infrastructure 
(CNKI), 
Wangfang 
Database 
searched to 2011 
None reported Four(Buvat et al 2009;Kaufman 
et al 2009;McMahon et al 
2010;Pryor et al 2006)  
AMSTAR score, 1/11: 
 - study quality assessed* 
Published subsequent to 
reported search date: 
one(Lee et al 2012) 
McCarty 
2012(McCarty 
& Dinsmore 
2012) 
(Ireland) 
 
Systematic review 
 
 
Dapoxetine 
(SSRI) 
PubMed, the 
Cochrane 
Database of 
Systematic 
Reviews, NHS 
Evidence, and 
the National 
Institute for 
Health and 
Clinical 
Excellence 
org.uk). To 
August 2011.  
Start date not 
reported 
The references 
listed in identified 
articles were used 
as a further source 
of relevant studies. 
Four(Buvat et al 2009;Kaufman 
et al 2009;McMahon et al 
2010;Safarinejad 2008)  
AMSTAR score, 2/11: 
 - characteristics of 
included studies reported 
 - conflict of interest 
statement reported 
Published subsequent to 
reported search date: 
one(Lee et al 2012) 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
McMahon 
2011(McMahon 
& Porst 2011) 
(Australia) 
 
Systematic review 
Any systemic 
treatment 
Waldinger 
2004(Waldinger 
et al 2004a) and 
PubMed from 
2004 (no end 
date) 
The references 
listed in identified 
articles were used 
as a further source 
of relevant studies. 
Five(Atmaca et al 2002;Kara et 
al 1996;Mattos et al 
2008;Waldinger et al 
1998;Waldinger et al 2001a) 
AMSTAR score, 2/11: 
 - characteristics of 
included studies reported 
 - conflict of interest 
statement reported 
Potentially missed: 
eleven(Ahn et al 
1996;Akgul et al 
2008;Arafa & Shamloul 
2006;Culba et al 
2008;Farnia et al 
2009;Giammusso et al 
1997;Nada et al 
2009;Rezakhaniha & 
Sirosbakht 
2010;Safarinejad 
2007;Tuncel et al 2008) 
 
Published subsequent to 
publication date: 
five(Khelaia et al 2012;Lee 
et al 2012;Nada et al 
2012;Shang et al 
2012;Weixing et al 2012)  
McMahon 
2012(McMahon 
2012) 
(Australia) 
 
Systematic review 
Dapoxetine 
(SSRI) 
MEDLINE, Web 
of Science, 
PICA, EMBASE 
1993 to April 
2012 
The proceedings of 
major international 
and regional 
scientific meetings. 
Four(Buvat et al 2009;Kaufman 
et al 2009) (McMahon et al 
2010;Pryor et al 2006) 
AMSTAR score, 4/11: 
 - comprehensive literature 
search 
 - studies included 
regardless of publication 
type 
 - characteristics of 
included studies reported 
 - conflict of interest 
statement reported 
Published subsequent to 
reported search date: 
one(Lee et al 2012) 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
Moreland 
2005(Moreland 
& Makela 2005) 
(USA) 
 
Described as a 
'mini review' 
Any SSRI Not reported None reported Nine(Atmaca et al 2002;Biri et 
al 1998;Manasia et al 
2003;McMahon & Touma 
1999;Mendels et al 
1995;Waldinger et al 
1997;Waldinger et al 
1998;Waldinger et al 
2001a;Waldinger et al 2001b) 
AMSTAR score, 0/11  Potentially missed: 
two(Ahn et al 
1996;Giammusso et al 
1997) 
 
Published subsequent to 
reported search date: 
ten(Akgul et al 2008;Arafa 
& Shamloul 2006;Culba et 
al 2008;Farnia et al 
2009;Khelaia et al 
2012;Lee et al 2012;Nada 
et al 2009;Nada et al 
2012;Rezakhaniha & 
Sirosbakht 
2010;Safarinejad 
2007;Shang et al 
2012;Tuncel et al 
2008;Weixing et al 2012) 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
Richardson 
2005(Richardson 
et al 2005)  
(UK) 
 
Systematic review 
Any systemic 
treatment 
MEDLINE,  
1966 to January 
2003 and 
PsycINFO, 1872 
to January 2003 
Manuscripts were 
hand-searched (not 
clear if this was 
hand searching 
specific relevant 
journals) and a 
search of published 
reviews and the 
references of 
included studies 
Seven(McMahon 
1998;McMahon & Touma 
1999;Waldinger et al 
1997;Waldinger et al 
1998;Waldinger et al 
2001a;Waldinger et al 
2001b;Yilmaz et al 1999) 
AMSTAR score, 1/11: 
 - characteristics of 
included studies reported 
Potentially missed: 
two(Ahn et al 
1996;Giammusso et al 
1997) 
 
Published subsequent to 
reported search date: 
thirteen(Akgul et al 
2008;Arafa & Shamloul 
2006;Culba et al 
2008;Farnia et al 
2009;Khelaia et al 
2012;Lee et al 2012;Nada 
et al 2009;Nada et al 
2012;Rezakhaniha & 
Sirosbakht 
2010;Safarinejad 
2007;Shang et al 
2012;Tuncel et al 
2008;Weixing et al 2012) 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
Waldinger 
2004(Waldinger 
et al 2004a) 
(Netherlands) 
 
Systematic review 
Any systemic 
or topical 
treatment 
MEDLINE 
(1966–2002), 
Web of Science, 
PICA, and 
EMBASE 
(1980–2002) 
The references 
listed in identified 
articles were used 
as a further source 
of relevant studies. 
Thirteen(Atmaca et al 2002;Biri 
et al 1998;Haensel et al. 
1998;Kara et al 1996;McMahon 
& Touma 1999;Novaretti et al. 
2002;Waldinger et al 
1994;Waldinger et al 
1997;Waldinger et al 
1998;Waldinger et al 
2001a;Waldinger et al 
2001b;Waldinger et al 
2003;Yilmaz et al 1999) 
AMSTAR score, 1/11: 
 - characteristics of 
included studies reported 
Potentially missed: 
two(Ahn et al 
1996;Giammusso et al 
1997) 
 
Published subsequent to 
reported search date: 
thirteen(Akgul et al 
2008;Arafa & Shamloul 
2006;Culba et al 
2008;Farnia et al 
2009;Khelaia et al 
2012;Lee et al 2012;Nada 
et al 2009;Nada et al 
2012;Rezakhaniha & 
Sirosbakht 
2010;Safarinejad 
2007;Shang et al 
2012;Tuncel et al 
2008;Weixing et al 2012) 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
Wang 
2007(Wang et al 
2007) 
(China) 
 
Systematic review 
Any SSRI MEDLINE 
January 1 1996 
to August 1 2006 
None reported Eight(Atmaca et al 
2003;McMahon 1998;Murat 
Basar et al 1999;Safarinejad & 
Hosseini 2006;Waldinger et al 
2001a;Waldinger et al 
2001b;Waldinger et al 
2003;Yilmaz et al 1999) 
AMSTAR score, 0/11 Potentially missed: 
two(Ahn et al 
1996;Giammusso et al 
1997) 
 
Published subsequent to 
reported search date: 
thirteen(Akgul et al 
2008;Arafa & Shamloul 
2006;Culba et al 
2008;Farnia et al 
2009;Khelaia et al 
2012;Lee et al 2012;Nada 
et al 2009;Nada et al 
2012;Rezakhaniha & 
Sirosbakht 
2010;Safarinejad 
2007;Shang et al 
2012;Tuncel et al 
2008;Weixing et al 2012) 
Wang 
2010(Wang et al 
2010) 
(China) 
 
Systematic and 
meta-analysis 
Dapoxetine 
(SSRI) 
The Cochrane 
Library, 
MEDLINE, 
EMBASE, China 
National 
Knowledge 
Infrastructure 
(CNKI), Chinese 
Biomedical 
Literature 
database (CBM), 
Chinese Science 
and Technology 
Periodical 
None reported Five(Buvat et al 2009;Kaufman 
et al 2009) 
(Pryor et al 2006;Safarinejad 
2008;Safarinejad 2006) 
AMSTAR score, 2/11: 
 - characteristics of 
included studies reported 
 - study quality assessed* 
Published subsequent to 
reported search date: 
one(Lee et al 2012) 
Author, review 
type, treatments 
included 
Treatments 
covered 
Databases 
searched and 
dates 
Additional 
searches 
undertaken by 
review 
Included RCTs of SSRIs AMSTAR review quality 
assessment 
Additional RCTs 
identified by our searches 
within and subsequent to 
search dates of existing 
reviews 
Database (VIP) 
From 1979 to 
2009 
AMSTAR review quality criteria: a priori' design, duplicate study selection and data extraction; comprehensive literature search of databases and other supplementary 
sources; studies included regardless of publication type; list of studies (included and excluded); characteristics of included studies reported; study quality assessed; study 
quality used to informed conclusions; appropriate methods used to pool data; publication bias assessed; conflict of interest statement included; *, Jadad scale (Jadad et al 
1996); †, modified Cochrane Collaboration risk of bias assessment criteria(Higgins et al 2011) 
 
3.3. Studies not included in existing reviews 
Our searches identified 16 RCTs that were not included in any existing review (Ahn et al. 1996;Akgul 
et al. 2008;Arafa and Shamloul 2006;Culba et al. 2008;Farnia et al. 2009;Giammusso et al. 
1997;Khelaia et al. 2012;Lee et al. 2012;Nada et al. 2009;Nada et al. 2012;Rezakhaniha and 
Sirosbakht 2010;Safarinejad & Hosseini 2006;Safarinejad 2007;Shang et al. 2012;Tuncel et al. 
2008;Weixing et al. 2012).  Seven of these were published subsequent to existing reviews (Khelaia et 
al. 2012; Nada et al. 2009;Nada et al. 2012;Rezakhaniha and Sirosbakht 2010;Safarinejad & Hosseini 
2006; Shang et al. 2012; Weixing et al. 2012).  However, nine RCTs  (Ahn et al 1996;Akgul et al 
2008;Arafa & Shamloul 2006;Culba et al 2008;Farnia et al 2009;Giammusso et al 1997;Lee et al 
2012;Safarinejad 2007;Tuncel et al 2008) appeared to have been missed or excluded from existing 
reviews’ search strategies as the publication date of the RCT was within the search dates reported by 
the existing reviews.   
The largest number of RCTs potentially missed by a review’s search strategy was eleven (Ahn et al 
1996;Akgul et al 2008;Arafa & Shamloul 2006;Culba et al 2008;Farnia et al 2009;Giammusso et al 
1997;Nada et al 2009;Rezakhaniha & Sirosbakht 2010;Safarinejad 2007;Tuncel et al 2008).  The 
review concerned (McMahon & Porst 2011), which evaluated any pharmacological treatment for PE 
including SSRIs, reported extracting RCT data from an existing review published in 2004 (Waldinger 
et al 2004a), combined with electronic searches for further relevant studies published from 2004 
onwards.   
3.4. Summary of the number of studies in both the rapid and full systematic review 
In summary: the same search was used for both the rapid review and full systematic review, the same 
41 RCTS were included in both the rapid review and the full systematic review; in the rapid, review 
data for 25 of the 41 RCTs were extracted from existing reviews, with data from 16 RCTs not 
reported in any review being extracted from the RCT full-text publication; in the full systematic 
review, data were extracted from the full-text publication for all 41 RCTs.  There were no additional 
RCTs included in the full systematic review that were not included in the rapid review. 
3.5. Accuracy of outcome data from existing reviews 
The primary outcome of interest for the HTA short report was intravaginal ejaculatory latency time 
(IELT).  When checked across reviews, IELT outcome data was consistent and no discrepancies were 
evident.  The most recent and comprehensive review in terms of the number of included RCTs across 
all SSRIs reported change from baseline values for IELT.(Huang et al 2009)  Although these authors 
did not report how they estimated variance estimates associated with the change from baseline values 
used in their analysis, the mean IELT values concurred with those reported in the original RCT 
publications.  In addition, all secondary outcome data including adverse event data reported by 
reviews concurred with those reported in the original RCT publication.  In summary, the error rate for 
RCT data extraction of IELT and secondary outcomes reported in existing reviews was low. 
3.6. Completeness of outcome data from existing reviews 
When checked against the RCT publication, all IELT data reported as a mean value with variance 
estimate were reported accurately when cross checked with existing reviews.  The only additional 
IELT data from the original RCT publications not reported by any review were as follows: one RCT 
reporting IELT results classified as unsuccessful, improvement and cure, (Murat Basar et al 1999) two 
RCTs reporting median and range values  for this outcome (Waldinger et al 1994;Waldinger et al 
1997) and two RCTs (Waldinger et al 2001a;Waldinger et al 2001b) reporting p-values for the 
between-group difference in geometric mean without any variance estimate (Supplementary table).  
These data were unsuitable for pooling with IELT data (mean and standard deviation) in the meta-
analysis undertaken as part of the HTA short report (Cooper et al 2013).  In terms of secondary 
efficacy outcomes, these were in general also consistent in terms of completeness of data extraction 
and reporting by existing reviews (Supplementary table).  The limiting factor in terms of secondary 
outcomes for pooling data across RCTs for the HTA short report was the varied and limited way these 
outcomes were assessed and reported in the original RCT publication and not the reporting in the 
reviews.  In summary, all RCT IELT outcome data required for our analysis for the HTA short report 
were available from existing reviews. 
Adverse event data reported by existing reviews was confirmed as accurate when compared against 
the original RCT publications.  Additional adverse event data not included in reviews was available 
from eleven RCTs.(Atmaca et al 2002;Biri et al 1998;Manasia et al 2003;McMahon 1998;Mendels et 
al 1995;Murat Basar et al 1999;Safarinejad & Hosseini 2006;Safarinejad 2006;Waldinger et al 
1994;Waldinger et al 1997;Waldinger et al 2003;Yilmaz et al 1999)  However, these data tended to be 
greater detail regarding types of adverse events and numbers of participants (Supplementary table ), 
and did not conflict with any conclusions regarding between-group differences in adverse events (e.g., 
reported p-values) presented in existing reviews.  Furthermore, due to diversity of the types of adverse 
events these data did not facilitate any data pooling across RCTs for adverse events in the HTA short 
report (Cooper et al 2013). 
3.7. Completeness and consistency of data on RCT quality taken from existing reviews 
Only four of the eleven existing reviews (36%) reported undertaking a quality assessment (Cong et al 
2012;Huang et al 2009;Luo et al 2012;Wang et al 2010). Two reviews (Cong et al 2012;Wang et al 
2010) reported applying the Jadad quality scale (Jadad et al 1996) with one review reporting a quality 
assessment cut-off of five points or above on the Jadad quality scale to include RCTs (Cong et al 
2012).  Two reviews (Huang et al 2009;Wang et al 2010) applied the Cochrane Collaboration risk of 
bias assessment criteria (Higgins et al 2011), however; it was unclear from the two reviews concerned 
how the Cochrane Collaboration risk of bias assessment criteria (Higgins et al 2011) had been 
converted to an overall grade.  Due to the diversity of quality assessment approaches and limited 
number of reviews reporting a quality assessment, we considered it unfeasible make any comparisons 
between the quality assessments reported by existing reviews and our quality assessment of the 
original RCT publications for this study using the Cochrane Collaboration risk of bias assessment 
criteria.  We did, however, undertake a Cochrane Collaboration risk of bias assessment on all 41 RCT 
publications obtained as full-text for the full systematic review for completeness (Supplementary 
table). 
3.8. Comparability of rapid review findings versus full systematic review findings 
The findings for the effectiveness of SSRIs in the treatment of PE, based on our HTA short report 
which included a meta-analysis of IELT outcomes, were that, with the exception of fluvoxamine, 
SSRIs are significantly more effective than placebo at increasing IELT, with the greatest increase 
evident for paroxetine, and that all SSRIs are associated with side effects.  However, the evidence 
comprised RCT data extracted from existing reviews which were of low to moderate methodological 
quality coupled with data extracted from RCT publications not already included in a review, the 
majority of which were of unclear risk of bias.(Cooper et al 2013) 
In terms of comparison of the two methods, the findings and conclusions arrived at from the rapid 
review method for safety and effectiveness of SSRIs in the treatment of PE adopted in our HTA short 
report, i.e., extracting RCT data from existing reviews, did not differ from those arrived at through 
undertaking a full systematic review extracting data directly from RCT publications.  IELT data 
reported in existing reviews were sufficiently complete and accurate and there was therefore no 
difference between the findings of the rapid and the full review for the primary outcome.  Of note, for 
the rapid review our electronic searches were run from database inception dates.  Had we run our 
searches from the last search date reported by our included reviews, some relevant studies would have 
been omitted (Table 2).  In terms of quality assessment, the information on study quality reported in 
existing reviews of SSRIs for premature ejaculation was limited across reviews and where undertaken 
was done so using a variety of assessment methods and we were only able to present study quality 
data for the 16 RCTs not included in reviews for the HTA short report which, along with the 
methodological quality of the existing reviews, was a limitation.  As such we undertook a 
comprehensive risk of bias assessment of all RCTs identified for inclusion as part of the full review 
by obtaining the full RCT publication.  The risk of bias assessment undertaken as part of the full 
review indicates that the majority of RCTs evaluating SSRIs for the treatment of premature 
ejaculation (38/41, 92.7% - supplementary table) are of unclear risk of detection bias, mainly due to 
limited reporting regarding blinding of the outcome assessment.  Sensitivity analyses for study quality 
were not planned as part of either the rapid or the full review. 
4. Discussion 
Within our de novo rapid review method reported here, we extracted RCT data reported in existing 
reviews of SSRIs for PE and combined these data with additional data extracted from RCTs not 
included in any existing review.  Our searches identified additional RCTs that had been either missed 
by existing reviews’ search strategies or inclusion criteria, or were published subsequently to the 
reported search dates of existing reviews.  The primary and secondary efficacy outcome data extracted 
directly from reviews were accurate and complete when compared with the original RCT 
publications, with the exception of a small amount of additional data not suitable for our data pooling, 
and some additional information regarding type and numbers of adverse events.  The findings of our 
rapid review for the effects of SSRIs in treating PE concurred with those that would have been 
reached had we undertaken a full systematic review in this area, extracting data from the original RCT 
publications.  However, we were only able to undertake an assessment of methodological quality of 
all RCTs as part of the full systematic review.  Reporting of study quality was limited and disparate 
across existing reviews. 
The rapid review approach we used allowed us to synthesise an evidence base comprising one 
hundred two (102) RCTs across all behavioural, systemic and topical treatments for PE, forty-one 
(41) of which evaluated SSRIs.  In addition, we were able to synthesise quantitative primary outcome 
data across RCTs where appropriate in a meta-analysis to produce effect estimates across all relevant 
RCTs.  This would not have been possible had we chosen to report and summarise the results from 
existing reviews separately to those from fully extracted additional RCTs, as with other approaches to 
rapid reviews (Khangura et al 2012).  We were also able to correct data synthesis errors (double 
counting of participants in meta-analyses) where evident in existing reviews.   
Existing systematic reviews might miss studies due to limitations of their search strategies or 
inclusion criteria, as was evident in some of the reviews included here.  The full systematic search we 
used as part of our rapid review method identified some RCTs apparently missed by existing reviews 
which, in terms of the research question, was a strength of our method.  However, subgroup analyses 
for the effects of missing studies were outside of the scope of our HTA short report.  Careful 
judgement should be made when employing rapid review methodology that uses existing reviews as 
to whether to search for additional RCT evidence subsequent to or including the search dates of 
existing reviews.  The decision regarding an appropriate cut-off date when searching for additional 
studies may also depend on the completeness of the reported search strategy in existing reviews 
(search terms and sources searched) and the inclusion/exclusion criteria for included studies (e.g., 
using a quality assessment cut-off) and whether these factors have the potential to miss potentially 
important studies.  In addition, decisions on whether to re-visit original RCT publications reported in 
reviews might be based on factors such as whether independent study selection, double data extraction 
and quality assessment of included studies are reported by the review or not.   
The overall methodological quality (AMSTAR(Shea et al 2007)) of the existing reviews included by 
this assessment was low and there was limited reporting of double-data extraction or methodological 
quality assessment of included studies.  However, we identified several reviews evaluating SSRIs in 
the treatment of PE that in this example of rapid reviewing helped facilitate data checking of RCT 
data across reviews, Whilst not all RCTs in reviews were reported by all of the reviews (owing to 
differences in search strategies, inclusion criteria and search dates), there was sufficient overlap (i.e., 
each RCT from a review was presented in two or more reviews) for cross-review data checking for 
accuracy.  Despite the methodological limitations evident in the existing reviews, the findings for the 
primary efficacy outcome (IELT) from our de novo rapid review method reported here would not 
differ from those arrived at through undertaking a full systematic review extracting data directly from 
RCT publications.  However, the limited reporting of assessment of methodological quality of include 
studies across reviews did not facilitate any meaningful interpretation of study quality and would not 
have facilitated a sensitivity analysis for study quality had this been an a priori defined outcome.  
Information on study quality could be extracted from systematic reviews in other research areas where 
quality assessment is better reported.  
Developed from methods to conduct systematic reviews, a diverse range of rapid review methods are 
currently reported in the literature.  A review of current methods and practice in Health Technology 
Assessment that compared rapid versus full systematic reviews in the areas of on the topics of drug 
eluting stents, lung volume reduction surgery, living donor liver transplantation and hip 
resurfacing reported that overall conclusions did not vary greatly in cases where both rapid and full 
systematic reviews were conducted (Cameron 2007).  However, there is limited agreement at present 
regarding the contents, method and definition of a rapid review (Watt et al 2008).  Furthermore, there 
is currently no agreed and tested methodology for rapid reviews and it is unclear how rapid reviews 
differ from systematic reviews (Harker & Kleijnen 2012).   
The advantages of the method reported here are that we were able to: identify RCTs missed by 
existing review searches and any subsequently published RCTs; cross-check RCT data for 
consistency as there was more than one review for each RCT; undertake a double data extraction due 
to time saved by extracting data from existing reviews; correct data synthesis errors in existing 
reviews; and pool data across all RCTs to produce effect estimates and to summarise the evidence 
base for behavioural, systemic and topical treatments in the treatment of PE to date.  Where only one 
review of RCT data is available, reliability of those data cannot be checked across other reviews.  In 
this scenario, revisiting original RCT publications might be more accurate and this decision may 
depend on the methodological quality and relevance of the existing review.  In terms of the research 
question, the main limitation to the validity of the rapid review method reported here compared with a 
full systematic review was that we were unable to check the methodological quality of RCTs reported 
in existing reviews and, where reported, the quality assessment reporting in existing reviews was 
limited and disparate.  Where methodological quality is disparate across one or more existing review, 
this may also necessitate obtaining the original RCT publication for a comprehensive quality 
assessment, especially where further RCTs not included in existing reviews are identified for 
inclusion. 
5. Conclusions and recommendations 
We evaluated a rapid review method in which RCT data were extracted from existing reviews and 
additional RCTs not already captured by any review, comparing it with a full systematic review 
method of the same topic – SSRIs for treating premature ejaculation.  As part of the comparison of 
review methods, we evaluated whether our rapid review approach was a reliable method in terms of 
study identification, data completeness, data accuracy, and information on study quality in this area, 
compared with a full systematic review method.  Searches run from database inception were used for 
both the rapid and the full review to identify relevant RCTs.  We found in this area of research that 
primary outcome data available for meta-analysis (IELT) were the same whether the de novo rapid 
review method or a full review method were employed.  However, due to limited reporting across 
reviews, quality assessment of all RCTs could only be undertaken as part of the full systematic 
review.  Reviewers wanting to undertake a sensitivity analysis of study quality might therefore have 
to access all RCT publications in full to do so, should adequate data on study quality not be reported 
by existing reviews.   
The existing systematic reviews in SSRIs for PE are of low to moderate methodological quality, the 
majority of which do not present an adequate quality assessment of included RCTs, which was a 
limitation observed by our rapid review in this area.  A strength of our rapid review was that the use 
of full systematic review searches identified both existing systematic reviews and the RCTs included 
in those reviews as well as RCTs that had not been captured by the existing reviews.  The limitations 
in reporting of study quality assessment in existing reviews that we observed might not be evident in 
systematic reviews in other areas and the rapid review methods reported here might therefore be 
useful when undertaking reviews within tight time constraints.   
The circumstances under which a rapid review in which data are extracted from existing reviews 
without obtaining included RCT publications in full might be considered to be satisfactory in 
comparison with undertaking a full systematic review are difficult to determine.  Reviewers should 
consider both the availability and the methodological quality of existing reviews if these are going to 
be used as the primary source of RCT data extraction rather than obtain the RCT publication in full.  
If existing reviews are planned to be used, in addition to aspects of robustness of the search strategy, 
inclusion criteria for studies, and methods for study selection and data extraction, consideration 
should also be given to the adequacy of any assessment of study quality undertaken by and reported in 
existing reviews, especially if a sensitivity analysis by study quality is planned.  These conclusions 
and recommendations are summarised in Table 3.  Reviewers using any rapid systematic approach to 
conduct a review should also fully acknowledge the limitations of the rapid method used compared 
with full systematic review methods. 
Table 3: Conclusions and recommendations 
Question Findings Conclusions Recommendations 
Did rapid review method 
identify relevant studies 
Some existing reviews 
missed potentially 
relevant studies 
Undertaking literature 
searches from database 
inception rather than 
search dates of exiting 
reviews identified these 
studies 
Existing reviews may 
miss relevant studies due 
to limitations in literature 
searching, study selection 
methods and inclusion 
criteria for studies 
Reviewers should 
consider whether to 
search for RCTs across 
all dates (as reported 
here) or just those 
published subsequent to 
existing review dates. 
This may be a balance 
between the time 
available and the 
methodological  
robustness and 
availability of existing 
reviews 
Data accuracy Outcome data in existing 
reviews of treatments for 
premature ejaculation 
appeared accurate when 
compared with the 
original RCT publication. 
The ability to cross-check 
data across multiple 
reviews in this area 
increased reliability. 
Accuracy of data in 
existing reviews may be 
limited by robustness of 
data extraction process.  
Limited reporting of 
secondary outcome data 
(e.g., adverse events) may 
be evident in existing 
reviews.  
Rapid reviewers should 
consider both the 
availability of existing 
reviews and their 
methodological and 
reporting quality 
Data completeness Primary outcome data 
across existing reviews of 
treatments for premature 
ejaculation were 
complete. Reporting of 
secondary outcome data 
was limited both within 
reviews and original RCT 
publications 
Existing reviews may be 
an adequate source of 
primary outcome data, 
providing that they are of 
adequate methodological 
and reporting quality. 
Availability of multiple 
reviews may optimise 
availability of data. 
If the rapid review aims 
to focus on primary 
outcome measures, and 
the availability, and 
methodological and 
reporting quality, of 
existing reviews are 
adequate, rapid reviewers 
could consider not 
obtaining the original 
RCT publications therein 
for additional data. 
Information on study 
quality 
Quality assessment and 
reporting of RCTs 
included in reviews of 
treatments for premature 
ejaculation was diverse, 
limited in its application, 
and poorly reported 
Quality assessment 
information of RCTs 
included in existing 
reviews may be reliable if 
it is undertaken using an 
appropriate assessment 
method in a consistent 
and is clearly reported. 
Rapid reviewers should 
consider the availability 
and quality of quality 
assessment with reviews. 
In some instances the 
original RCT publications 
may be required in order 
to undertake a 
standardised quality 
assessment across all 
RCTs 
Question Findings Conclusions Recommendations 
Similarity of conclusions 
between rapid and full 
reviews 
In this case, the overall 
findings of our rapid 
review concurred with 
those that would have 
been reached had we 
undertaken a full 
systematic review, 
extracting data from the 
original RCT publications 
We feel that our method 
represents a reasonable 
alternative where 
resources for a full 
review are not available, 
and is likely to provide 
similar overall 
conclusions to a full 
review in most cases. The 
extent of similarity of 
conclusions using our 
method is likely to 
depend on the inclusion 
criteria and study quality 
of existing reviews 
Rapid reviewers and 
commissioners may wish 
to check the availability, 
relevance (inclusion 
criteria) and 
methodological quality of  
existing reviews before 
deciding whether our 
rapid review method is 
likely to yield similar 
results to a full systematic 
review. 
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